Gary Titus
Direttore/Membro del Consiglio presso BioSight Ltd.
Posizioni attive di Gary Titus
Società | Posizione | Inizio | Fine |
---|---|---|---|
BioSight Ltd.
BioSight Ltd. Miscellaneous Commercial ServicesCommercial Services BioSight Ltd. is a clinical stage biotechnology company engaging in the development of therapeutics for hematological malignancies and disorders. The company was founded by Stela Gengrinovitchan and Mark Gengrinovitch on November 10, 1999 and is headquartered in Lod, Isreal. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Gary Titus
Precedenti posizioni note di Gary Titus
Società | Posizione | Inizio | Fine |
---|---|---|---|
PLUS THERAPEUTICS, INC. | Direttore Finanziario/CFO | 01/04/2019 | 05/07/2019 |
Segretario Aziendale | 01/04/2019 | 05/07/2019 | |
UROGEN PHARMA LTD. | Direttore Finanziario/CFO | 01/07/2015 | 05/06/2018 |
BioCardia, Inc. /Old/
BioCardia, Inc. /Old/ BiotechnologyHealth Technology BioCardia, Inc. is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The firm develops two comprehensive biotherapeutic products for cardiac arrest; CardiAMP and CardiALLO. CardiAMP is a bone marrow derived cell-based therapy for ischemic systolic heart failure patients who are not actively ischemic. CardiALLo is a allogeneic culture expanded mesenchymal bone marrow cells from a universal donor for use in multiple unrelated patients, entering Phase II development. Its other products also include Helix System and Morph Products. The company was founded in March 2002 and is headquartered in San Carlos, CA. | Direttore Finanziario/CFO | 01/05/2014 | 01/01/2015 |
SCICLONE PHARMACEUTICALS, INC. | Direttore Finanziario/CFO | 08/12/2008 | 31/05/2013 |
Public Communications Contact | 08/12/2008 | 31/05/2013 | |
Kosan Biosciences, Inc.
Kosan Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Kosan Biosciences, Inc. develops drugs for cancer therapeutics. The company was founded in 1995 and is headquartered in New York, NY. | Direttore Finanziario/CFO | 01/09/2006 | 01/09/2008 |
Nuvelo, Inc. | Comptroller/Controller/Auditor | 01/01/2003 | 01/09/2006 |
Direttore Finanziario/CFO | 01/01/2003 | 01/09/2006 | |
CYMABAY THERAPEUTICS, INC. | Direttore Finanziario/CFO | 01/01/2002 | 01/01/2003 |
IntraBiotics Pharmaceuticals, Inc.
IntraBiotics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology IntraBiotics, a developer of antibiotics and antifungals is focused on one drug candidate, iseganan hydrochloride oral solution, which would be used for the prevention of ventilator-associated pneumonia and to help cystic fibrosis patients fight respiratory infections. | Direttore Finanziario/CFO | 01/01/2000 | 01/01/2002 |
░░░░░░░ ░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░ ░░░░░░░░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ | - |
Formazione di Gary Titus
University of Florida | Undergraduate Degree |
University of South Florida | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 13 |
Israele | 2 |
Posizioni
Director of Finance/CFO | 8 |
Undergraduate Degree | 2 |
Director/Board Member | 2 |
Settori
Health Technology | 11 |
Consumer Services | 3 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 3 |
---|---|
JOHNSON & JOHNSON | Health Technology |
UROGEN PHARMA LTD. | Health Technology |
PLUS THERAPEUTICS, INC. | Health Technology |
Aziende private | 8 |
---|---|
Nuvelo, Inc. | Health Technology |
Kosan Biosciences, Inc.
Kosan Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Kosan Biosciences, Inc. develops drugs for cancer therapeutics. The company was founded in 1995 and is headquartered in New York, NY. | Health Technology |
CymaBay Therapeutics, Inc.
CymaBay Therapeutics, Inc. BiotechnologyHealth Technology CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA. | Health Technology |
IntraBiotics Pharmaceuticals, Inc.
IntraBiotics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology IntraBiotics, a developer of antibiotics and antifungals is focused on one drug candidate, iseganan hydrochloride oral solution, which would be used for the prevention of ventilator-associated pneumonia and to help cystic fibrosis patients fight respiratory infections. | Health Technology |
SciClone Pharmaceuticals LLC
SciClone Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology SciClone Pharmaceuticals LLC was engaged in the development of therapeutic treatment for oncology, infectious diseases, and cardiovascular disorders. It was also offering ZADAXIN for the treatment of hepatitis B, hepatitis C, certain cancers, and used as immune system enhancer, and DC Bead which is used for the novel treatment of liver cancer. The company was founded in 1990 and was headquartered in San Mateo, CA. | Health Technology |
ImmunoCellular Therapeutics Ltd.
ImmunoCellular Therapeutics Ltd. BiotechnologyHealth Technology ImmunoCellular Therapeutics, Ltd. is a clinical-stage pharmaceutical company, focused on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. The company was founded on March 20, 1987 and is headquartered in Montvale, NJ. | Health Technology |
BioCardia, Inc. /Old/
BioCardia, Inc. /Old/ BiotechnologyHealth Technology BioCardia, Inc. is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The firm develops two comprehensive biotherapeutic products for cardiac arrest; CardiAMP and CardiALLO. CardiAMP is a bone marrow derived cell-based therapy for ischemic systolic heart failure patients who are not actively ischemic. CardiALLo is a allogeneic culture expanded mesenchymal bone marrow cells from a universal donor for use in multiple unrelated patients, entering Phase II development. Its other products also include Helix System and Morph Products. The company was founded in March 2002 and is headquartered in San Carlos, CA. | Health Technology |
BioSight Ltd.
BioSight Ltd. Miscellaneous Commercial ServicesCommercial Services BioSight Ltd. is a clinical stage biotechnology company engaging in the development of therapeutics for hematological malignancies and disorders. The company was founded by Stela Gengrinovitchan and Mark Gengrinovitch on November 10, 1999 and is headquartered in Lod, Isreal. | Commercial Services |
- Borsa valori
- Insiders
- Gary Titus
- Esperienza